Can-Fite Cancer Drug to Enter Phase I Trial
Posted on: Wednesday, 9 January 2008, 09:01 CST
The FDA has granted approval to Can-Fite BioPharma to conduct a Phase I study with its second pipeline liver cancer drug, CF102.
A Phase I study in healthy volunteers will be conducted in the US by a clinical research organization (CRO) in a Phase I unit. Can-Fite estimates that this study will be initiated in the first quarter of 2008, and results should be published by the end of the first quarter of 2008.
Pnina Fishman, CEO of Can-Fite, said: "The initiation of this study is a substantial progress for the company, since it reflects the expansion of our development pipeline with a drug for additional indication. There are almost no competing therapies for liver cancer and there is a market need because the response rate of these patients to curative chemotherapy is very low. Our drug works through a unique mechanism that allows liver cancer cells to be targeted and attacked with high specificity."
Source: Datamonitor
Related Articles
- Celsion Provides Update on Its Global Pivotal Phase III Primary Liver Cancer Trial
- ITI Initiates Phase II Study of Insomnia Drug
- Study: Cancer Drug Gleevec Has Heart Risk
- Study: Cancer Drug May Pose Heart Danger
- Study Examines Side Effects of Breast Cancer Prevention Drugs
- Study of Arthritis Drugs Shows Cancer Risk is Small
- Dr. Barry Reisberg and Associates Conclude One Year Study on Alzheimer's Drug, Memantine
- Studies Find Statin Drugs Dont Cut Cancer Risk
- Predicting the Outcome of Drug-induced Liver Disease
- Cancer 'Wonder Drug' Brings New Hope for Women Treatment for Breast Disease Approved for Scots Patients
 |
 |
User Comments (0)
RSS Feeds